Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precision Medicine | 2 | 2018 | 111 | 1.100 |
Why?
|
| Electronic Health Records | 4 | 2019 | 374 | 1.010 |
Why?
|
| Computational Biology | 4 | 2016 | 190 | 0.930 |
Why?
|
| Ecosystem | 1 | 2022 | 54 | 0.800 |
Why?
|
| Glycomics | 1 | 2022 | 29 | 0.790 |
Why?
|
| Proteoglycans | 2 | 2022 | 103 | 0.680 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 88 | 0.640 |
Why?
|
| Data Mining | 2 | 2015 | 45 | 0.600 |
Why?
|
| Forecasting | 1 | 2018 | 277 | 0.590 |
Why?
|
| Medical Informatics | 2 | 2016 | 71 | 0.590 |
Why?
|
| Database Management Systems | 2 | 2015 | 25 | 0.580 |
Why?
|
| Software | 3 | 2015 | 418 | 0.570 |
Why?
|
| Algorithms | 3 | 2013 | 1195 | 0.550 |
Why?
|
| Computer Communication Networks | 1 | 2015 | 28 | 0.510 |
Why?
|
| Access to Information | 1 | 2015 | 21 | 0.500 |
Why?
|
| Mutation | 2 | 2011 | 1213 | 0.490 |
Why?
|
| Glycosaminoglycans | 1 | 2015 | 88 | 0.490 |
Why?
|
| Clinical Nursing Research | 1 | 2014 | 17 | 0.480 |
Why?
|
| Oncology Nursing | 1 | 2014 | 24 | 0.480 |
Why?
|
| Databases, Factual | 3 | 2018 | 621 | 0.460 |
Why?
|
| Mental Disorders | 1 | 2019 | 659 | 0.460 |
Why?
|
| Information Dissemination | 1 | 2015 | 113 | 0.460 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 711 | 0.450 |
Why?
|
| Biomarkers, Tumor | 2 | 2008 | 508 | 0.440 |
Why?
|
| Critical Care | 1 | 2015 | 263 | 0.420 |
Why?
|
| Internet | 1 | 2015 | 390 | 0.410 |
Why?
|
| Models, Theoretical | 1 | 2015 | 384 | 0.400 |
Why?
|
| Pediatrics | 1 | 2015 | 341 | 0.400 |
Why?
|
| Neoplasms | 2 | 2014 | 1664 | 0.390 |
Why?
|
| Artificial Intelligence | 3 | 2015 | 159 | 0.390 |
Why?
|
| Phenotype | 1 | 2014 | 946 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 929 | 0.360 |
Why?
|
| Glioblastoma | 1 | 2013 | 219 | 0.350 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 371 | 0.330 |
Why?
|
| Genetic Markers | 1 | 2008 | 144 | 0.320 |
Why?
|
| Chromosome Mapping | 1 | 2008 | 188 | 0.320 |
Why?
|
| Models, Genetic | 1 | 2008 | 161 | 0.310 |
Why?
|
| Gene Expression Profiling | 2 | 2007 | 498 | 0.290 |
Why?
|
| Lung Neoplasms | 2 | 2007 | 1172 | 0.290 |
Why?
|
| Decision Trees | 1 | 2007 | 74 | 0.280 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 307 | 0.270 |
Why?
|
| Genomics | 2 | 2018 | 168 | 0.260 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 627 | 0.260 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 786 | 0.250 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 560 | 0.220 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 778 | 0.220 |
Why?
|
| Informatics | 1 | 2022 | 3 | 0.210 |
Why?
|
| Models, Molecular | 2 | 2015 | 546 | 0.200 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 475 | 0.200 |
Why?
|
| Patient Portals | 1 | 2021 | 12 | 0.190 |
Why?
|
| Humans | 12 | 2021 | 68549 | 0.190 |
Why?
|
| Polysaccharides | 1 | 2022 | 176 | 0.180 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 85 | 0.170 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 1533 | 0.160 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 329 | 0.140 |
Why?
|
| Proteomics | 1 | 2018 | 246 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1549 | 0.130 |
Why?
|
| Interleukin-6 | 1 | 2017 | 330 | 0.130 |
Why?
|
| Computer Systems | 1 | 2015 | 42 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 1753 | 0.130 |
Why?
|
| Databases as Topic | 1 | 2015 | 49 | 0.130 |
Why?
|
| Clinical Studies as Topic | 1 | 2015 | 7 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2018 | 310 | 0.130 |
Why?
|
| Systems Integration | 1 | 2015 | 30 | 0.120 |
Why?
|
| Health Information Systems | 1 | 2014 | 18 | 0.120 |
Why?
|
| Prognosis | 2 | 2013 | 2093 | 0.120 |
Why?
|
| Gene Expression | 2 | 2007 | 770 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2015 | 652 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 536 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2013 | 193 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2011 | 219 | 0.090 |
Why?
|
| Inflammation | 1 | 2017 | 1030 | 0.090 |
Why?
|
| Survival Rate | 1 | 2013 | 1055 | 0.090 |
Why?
|
| Research Design | 1 | 2014 | 729 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2550 | 0.080 |
Why?
|
| Utah | 1 | 2008 | 27 | 0.080 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2008 | 75 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2008 | 159 | 0.070 |
Why?
|
| User-Computer Interface | 1 | 2009 | 230 | 0.070 |
Why?
|
| DNA, Complementary | 1 | 2007 | 251 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 791 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 320 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2008 | 706 | 0.060 |
Why?
|
| Male | 3 | 2021 | 37283 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2005 | 714 | 0.050 |
Why?
|
| Female | 2 | 2019 | 38021 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2008 | 2004 | 0.050 |
Why?
|
| Adult | 1 | 2019 | 21379 | 0.050 |
Why?
|
| Prostatectomy | 1 | 2021 | 87 | 0.050 |
Why?
|
| Risk Factors | 1 | 2008 | 5720 | 0.040 |
Why?
|
| Transgenes | 1 | 2017 | 92 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 86 | 0.040 |
Why?
|
| Oncogenes | 1 | 2017 | 71 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 110 | 0.030 |
Why?
|
| Prostate | 1 | 2017 | 116 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2017 | 221 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 235 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 1033 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2017 | 2689 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 8474 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 20880 | 0.010 |
Why?
|